Seek Returns logo

BMRN vs. MTD: A Head-to-Head Stock Comparison

Updated on

Here’s a clear look at BMRN and MTD, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.

Company Profile

SymbolBMRNMTD
Company NameBioMarin Pharmaceutical Inc.Mettler-Toledo International Inc.
CountryUnited StatesUnited States
GICS SectorHealth CareHealth Care
GICS IndustryBiotechnologyLife Sciences Tools & Services
Market Capitalization11.19 billion USD27.27 billion USD
ExchangeNasdaqGSNYSE
Listing DateJuly 26, 1999November 14, 1997
Security TypeCommon StockCommon Stock

Historical Performance

This chart compares the performance of BMRN and MTD by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.

BMRN vs. MTD: Growth of a $10,000 investment over the past one year.

Historical Performance at a Glance

SymbolBMRNMTD
5-Day Price Return-1.95%7.04%
13-Week Price Return-5.00%12.73%
26-Week Price Return-9.39%-2.45%
52-Week Price Return-34.52%-3.92%
Month-to-Date Return0.78%7.33%
Year-to-Date Return-11.30%8.20%
10-Day Avg. Volume3.38M0.19M
3-Month Avg. Volume2.22M0.20M
3-Month Volatility27.90%35.01%
Beta0.341.41

Profitability

Return on Equity (TTM)

BMRN

11.48%

Biotechnology Industry

Max
77.14%
Q3
10.76%
Median
-20.08%
Q1
-42.71%
Min
-119.20%

In the upper quartile for the Biotechnology industry, BMRN’s Return on Equity of 11.48% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.

MTD

1,675.84%

Life Sciences Tools & Services Industry

Max
19.96%
Q3
11.55%
Median
6.22%
Q1
3.86%
Min
-6.95%

MTD’s Return on Equity of 1,675.84% is exceptionally high, placing it well beyond the typical range for the Life Sciences Tools & Services industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.

BMRN vs. MTD: A comparison of their Return on Equity (TTM) against their respective Biotechnology and Life Sciences Tools & Services industry benchmarks.

Net Profit Margin (TTM)

BMRN

21.45%

Biotechnology Industry

Max
59.44%
Q3
16.21%
Median
-11.49%
Q1
-167.42%
Min
-409.07%

A Net Profit Margin of 21.45% places BMRN in the upper quartile for the Biotechnology industry, signifying strong profitability and more effective cost management than most of its peers.

MTD

21.46%

Life Sciences Tools & Services Industry

Max
27.28%
Q3
16.17%
Median
7.24%
Q1
3.00%
Min
-3.05%

A Net Profit Margin of 21.46% places MTD in the upper quartile for the Life Sciences Tools & Services industry, signifying strong profitability and more effective cost management than most of its peers.

BMRN vs. MTD: A comparison of their Net Profit Margin (TTM) against their respective Biotechnology and Life Sciences Tools & Services industry benchmarks.

Operating Profit Margin (TTM)

BMRN

25.33%

Biotechnology Industry

Max
60.62%
Q3
20.76%
Median
-12.41%
Q1
-181.14%
Min
-482.02%

An Operating Profit Margin of 25.33% places BMRN in the upper quartile for the Biotechnology industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.

MTD

26.49%

Life Sciences Tools & Services Industry

Max
33.15%
Q3
19.34%
Median
13.02%
Q1
8.05%
Min
-4.38%

An Operating Profit Margin of 26.49% places MTD in the upper quartile for the Life Sciences Tools & Services industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.

BMRN vs. MTD: A comparison of their Operating Profit Margin (TTM) against their respective Biotechnology and Life Sciences Tools & Services industry benchmarks.

Profitability at a Glance

SymbolBMRNMTD
Return on Equity (TTM)11.48%1,675.84%
Return on Assets (TTM)9.24%25.15%
Net Profit Margin (TTM)21.45%21.46%
Operating Profit Margin (TTM)25.33%26.49%
Gross Profit Margin (TTM)79.56%59.94%

Financial Strength

Current Ratio (MRQ)

BMRN

5.56

Biotechnology Industry

Max
19.31
Q3
9.38
Median
4.54
Q1
2.45
Min
0.76

BMRN’s Current Ratio of 5.56 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.

MTD

1.12

Life Sciences Tools & Services Industry

Max
4.76
Q3
2.77
Median
1.85
Q1
1.40
Min
0.43

MTD’s Current Ratio of 1.12 falls into the lower quartile for the Life Sciences Tools & Services industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.

BMRN vs. MTD: A comparison of their Current Ratio (MRQ) against their respective Biotechnology and Life Sciences Tools & Services industry benchmarks.

Debt-to-Equity Ratio (MRQ)

BMRN

0.10

Biotechnology Industry

Max
1.35
Q3
0.64
Median
0.09
Q1
0.00
Min
0.00

BMRN’s Debt-to-Equity Ratio of 0.10 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.

MTD

81.23

Life Sciences Tools & Services Industry

Max
1.75
Q3
0.83
Median
0.41
Q1
0.18
Min
0.00

With a Debt-to-Equity Ratio of 81.23, MTD operates with exceptionally high leverage compared to the Life Sciences Tools & Services industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.

BMRN vs. MTD: A comparison of their Debt-to-Equity Ratio (MRQ) against their respective Biotechnology and Life Sciences Tools & Services industry benchmarks.

Interest Coverage Ratio (TTM)

BMRN

-21.18

Biotechnology Industry

Max
72.37
Q3
1.91
Median
-7.81
Q1
-63.90
Min
-153.80

BMRN has a negative Interest Coverage Ratio of -21.18. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.

MTD

15.60

Life Sciences Tools & Services Industry

Max
29.61
Q3
23.24
Median
6.07
Q1
2.18
Min
-14.08

MTD’s Interest Coverage Ratio of 15.60 is positioned comfortably within the norm for the Life Sciences Tools & Services industry, indicating a standard and healthy capacity to cover its interest payments.

BMRN vs. MTD: A comparison of their Interest Coverage Ratio (TTM) against their respective Biotechnology and Life Sciences Tools & Services industry benchmarks.

Financial Strength at a Glance

SymbolBMRNMTD
Current Ratio (MRQ)5.561.12
Quick Ratio (MRQ)3.600.67
Debt-to-Equity Ratio (MRQ)0.1081.23
Interest Coverage Ratio (TTM)-21.1815.60

Growth

Revenue Growth

BMRN vs. MTD: A side-by-side comparison of their Revenue Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

EPS Growth

BMRN vs. MTD: A side-by-side comparison of their EPS Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

Dividend

Dividend Yield (TTM)

BMRN

0.00%

Biotechnology Industry

Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

BMRN currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.

MTD

0.00%

Life Sciences Tools & Services Industry

Max
1.80%
Q3
0.78%
Median
0.37%
Q1
0.00%
Min
0.00%

MTD currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.

BMRN vs. MTD: A comparison of their Dividend Yield (TTM) against their respective Biotechnology and Life Sciences Tools & Services industry benchmarks.

Dividend Payout Ratio (TTM)

BMRN

0.00%

Biotechnology Industry

Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

BMRN has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.

MTD

0.00%

Life Sciences Tools & Services Industry

Max
156.00%
Q3
65.73%
Median
23.81%
Q1
0.00%
Min
0.00%

MTD has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.

BMRN vs. MTD: A comparison of their Dividend Payout Ratio (TTM) against their respective Biotechnology and Life Sciences Tools & Services industry benchmarks.

Dividend at a Glance

SymbolBMRNMTD
Dividend Yield (TTM)0.00%0.00%
Dividend Payout Ratio (TTM)0.00%0.00%

Valuation

Price-to-Earnings Ratio (TTM)

BMRN

16.81

Biotechnology Industry

Max
60.14
Q3
38.17
Median
29.01
Q1
15.12
Min
0.00

BMRN’s P/E Ratio of 16.81 is within the middle range for the Biotechnology industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.

MTD

32.63

Life Sciences Tools & Services Industry

Max
117.96
Q3
65.59
Median
37.26
Q1
27.51
Min
1.73

MTD’s P/E Ratio of 32.63 is within the middle range for the Life Sciences Tools & Services industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.

BMRN vs. MTD: A comparison of their Price-to-Earnings Ratio (TTM) against their respective Biotechnology and Life Sciences Tools & Services industry benchmarks.

Price-to-Sales Ratio (TTM)

BMRN

3.61

Biotechnology Industry

Max
76.98
Q3
36.53
Median
9.49
Q1
4.49
Min
0.00

In the lower quartile for the Biotechnology industry, BMRN’s P/S Ratio of 3.61 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.

MTD

7.00

Life Sciences Tools & Services Industry

Max
12.46
Q3
6.70
Median
4.24
Q1
2.68
Min
0.73

MTD’s P/S Ratio of 7.00 is in the upper echelon for the Life Sciences Tools & Services industry. This means the company is valued richly on its revenue stream compared to its peers, suggesting the stock is priced for a high level of future performance.

BMRN vs. MTD: A comparison of their Price-to-Sales Ratio (TTM) against their respective Biotechnology and Life Sciences Tools & Services industry benchmarks.

Price-to-Book Ratio (MRQ)

BMRN

1.75

Biotechnology Industry

Max
20.53
Q3
9.76
Median
4.77
Q1
2.49
Min
0.59

BMRN’s P/B Ratio of 1.75 is in the lower quartile for the Biotechnology industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.

MTD

1,299.40

Life Sciences Tools & Services Industry

Max
7.99
Q3
4.69
Median
3.30
Q1
1.88
Min
1.02

At 1,299.40, MTD’s P/B Ratio is at an extreme premium to the Life Sciences Tools & Services industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.

BMRN vs. MTD: A comparison of their Price-to-Book Ratio (MRQ) against their respective Biotechnology and Life Sciences Tools & Services industry benchmarks.

Valuation at a Glance

SymbolBMRNMTD
Price-to-Earnings Ratio (TTM)16.8132.63
Price-to-Sales Ratio (TTM)3.617.00
Price-to-Book Ratio (MRQ)1.751,299.40
Price-to-Free Cash Flow Ratio (TTM)15.9931.94